Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults

The summary for the Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults grant is detailed below. This summary states who is eligible for the grant, how much grant money will be awarded, current and past deadlines, Catalog of Federal Domestic Assistance (CFDA) numbers, and a sampling of similar government grants. Verify the accuracy of the data FederalGrants.com provides by visiting the webpage noted in the Link to Full Announcement section or by contacting the appropriate person listed as the Grant Announcement Contact. If any section is incomplete, please visit the website for the National Institutes of Health, which is the U.S. government agency offering this grant.

Consortium Therapeutic Studies of Primary Central Nervous System Malignancies in Adults: The purpose of this RFA is for the Cancer Therapy Evaluation Program (CTEP) and the Radiation Research Program (RRP) of the Division of Cancer Treatment and Diagnosis (DCTD) at the National Cancer Institute (NCI) to invite the members of the North American Brain Tumor Consortium (NABTC) and the New Approaches to Brain Tumor Therapy (NABTT) consortium to submit new or competing continuation cooperative agreement applications. Each consortium of institutions will be referred to as a Central Nervous System Consortium (CNSC) for the purpose of this RFA. Members from both CNSCs will again be expected to perform Phase I and II clinical evaluations of promising new therapeutic agents or approaches for the treatment of primary CNS malignancies in adult patients, especially glioblastoma multiforme and other high-grade gliomas, and to perform ancillary laboratory studies of aspects of CNS tumor biology with potential clinical implications. The NCI desires to continue its support of talented scientists who will interact with other members of the consortium, and with NCI in a concerted way to conceive, create, and evaluate new approaches to the therapy of CNS tumors. The NCI anticipates continued funding of two CNSCs. Separate applications are requested from each current full and provisional member institution interested in continuing participation in their respective CNSC. Applications will only be accepted from current full and provisional member institutions of NABTC or NABTT. Each CNSC will include a single Central Operations Office/Coordinating Center responsible for meeting the administrative/regulatory requirements of the Consortium and for collecting/analyzing clinical data from participating institutions, a Pharmacokinetics Center, and a cohort of Participant Member Institutions providing patient resources. The proposed Central Operations Office/Coordinating Center of each CNSC should indicate which participating institutions will provide organizational support, scientific leadership, laboratory capabilities, and/or patient resources as well as pharmacokinetics expertise/facilities. Applications should indicate whether they are for the Central Operations Office/Coordinating Center, Pharmacokinetics Center, or Participant Member Institution providing patient resources. While a single application may propose only one of these roles, eligible institutions may submit separate applications for one or more of these different roles. It is anticipated that there will be only one application for the Central Operations Office/Coordinating Center of each CNSC. It is also anticipated that there will be only one application for the Pharmacokinetics Center of each CNSC.